Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46

Michael Dale Lairmore, Donna L. Rudolph, Beverly D. Roberts, Charlene S. Dezzutti, Renu B. Lal

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The immune response elicited by a synthetic peptide derived from an immunodominant external envelope region (Env-5, amino acids 242-257) of human T-lymphotropic virus type 1 (HTLV-I) was tested in a rabbit model of HTLV-I infection. The synthetic peptide elicited a strong antibody response to the HTLV-I envelope protein gp46; however, these antibodies failed to inhibit HTLV-I-mediated cell fusion. Immunized rabbits were not protected from HTLV-I infection as determined by seroconversion to viral core proteins by immunoblot, HTLV-I p24 antigen detection in lymphocyte cultures and polymerase chain reaction for the HTLV-I provirus in lymphocyte DNA. Env-5 peptide immunization failed to induce T-cell lymphocyte proliferative responses in rabbits, but induced antibody responses in T-cell deficient Balb c nu/nu mice suggesting that the antigenic determinant represented by the Env-5 peptide is primarily a B-cell epitope. These results further define an immunodominant epitope of the HTLV-I envelope protein and suggest that potential synthetic peptide vaccines against HTLV-I infection must contain multiple antigens that induce both humoral and cellular immune reactivity.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
JournalCancer Letters
Volume66
Issue number1
DOIs
StatePublished - Sep 14 1992
Externally publishedYes

Fingerprint

B-Lymphocyte Epitopes
Immunodominant Epitopes
Human T-lymphotropic virus 1
Virus Diseases
Viral Envelope Proteins
Peptides
Lymphocytes
Rabbits
Antibody Formation
Viral Core Proteins
T-Lymphocytes
Antigens
Proviruses
Synthetic Vaccines
Subunit Vaccines
Cell Fusion
Epitopes
Immunization
Amino Acids
Polymerase Chain Reaction

Keywords

  • animal model
  • human
  • human T-lymphotropic virus type 1
  • synthetic peptide
  • vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46. / Lairmore, Michael Dale; Rudolph, Donna L.; Roberts, Beverly D.; Dezzutti, Charlene S.; Lal, Renu B.

In: Cancer Letters, Vol. 66, No. 1, 14.09.1992, p. 11-20.

Research output: Contribution to journalArticle

Lairmore, Michael Dale ; Rudolph, Donna L. ; Roberts, Beverly D. ; Dezzutti, Charlene S. ; Lal, Renu B. / Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46. In: Cancer Letters. 1992 ; Vol. 66, No. 1. pp. 11-20.
@article{5a42376fed6f4d269c573f8c0a525233,
title = "Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46",
abstract = "The immune response elicited by a synthetic peptide derived from an immunodominant external envelope region (Env-5, amino acids 242-257) of human T-lymphotropic virus type 1 (HTLV-I) was tested in a rabbit model of HTLV-I infection. The synthetic peptide elicited a strong antibody response to the HTLV-I envelope protein gp46; however, these antibodies failed to inhibit HTLV-I-mediated cell fusion. Immunized rabbits were not protected from HTLV-I infection as determined by seroconversion to viral core proteins by immunoblot, HTLV-I p24 antigen detection in lymphocyte cultures and polymerase chain reaction for the HTLV-I provirus in lymphocyte DNA. Env-5 peptide immunization failed to induce T-cell lymphocyte proliferative responses in rabbits, but induced antibody responses in T-cell deficient Balb c nu/nu mice suggesting that the antigenic determinant represented by the Env-5 peptide is primarily a B-cell epitope. These results further define an immunodominant epitope of the HTLV-I envelope protein and suggest that potential synthetic peptide vaccines against HTLV-I infection must contain multiple antigens that induce both humoral and cellular immune reactivity.",
keywords = "animal model, human, human T-lymphotropic virus type 1, synthetic peptide, vaccine",
author = "Lairmore, {Michael Dale} and Rudolph, {Donna L.} and Roberts, {Beverly D.} and Dezzutti, {Charlene S.} and Lal, {Renu B.}",
year = "1992",
month = "9",
day = "14",
doi = "10.1016/0304-3835(92)90274-Y",
language = "English (US)",
volume = "66",
pages = "11--20",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46

AU - Lairmore, Michael Dale

AU - Rudolph, Donna L.

AU - Roberts, Beverly D.

AU - Dezzutti, Charlene S.

AU - Lal, Renu B.

PY - 1992/9/14

Y1 - 1992/9/14

N2 - The immune response elicited by a synthetic peptide derived from an immunodominant external envelope region (Env-5, amino acids 242-257) of human T-lymphotropic virus type 1 (HTLV-I) was tested in a rabbit model of HTLV-I infection. The synthetic peptide elicited a strong antibody response to the HTLV-I envelope protein gp46; however, these antibodies failed to inhibit HTLV-I-mediated cell fusion. Immunized rabbits were not protected from HTLV-I infection as determined by seroconversion to viral core proteins by immunoblot, HTLV-I p24 antigen detection in lymphocyte cultures and polymerase chain reaction for the HTLV-I provirus in lymphocyte DNA. Env-5 peptide immunization failed to induce T-cell lymphocyte proliferative responses in rabbits, but induced antibody responses in T-cell deficient Balb c nu/nu mice suggesting that the antigenic determinant represented by the Env-5 peptide is primarily a B-cell epitope. These results further define an immunodominant epitope of the HTLV-I envelope protein and suggest that potential synthetic peptide vaccines against HTLV-I infection must contain multiple antigens that induce both humoral and cellular immune reactivity.

AB - The immune response elicited by a synthetic peptide derived from an immunodominant external envelope region (Env-5, amino acids 242-257) of human T-lymphotropic virus type 1 (HTLV-I) was tested in a rabbit model of HTLV-I infection. The synthetic peptide elicited a strong antibody response to the HTLV-I envelope protein gp46; however, these antibodies failed to inhibit HTLV-I-mediated cell fusion. Immunized rabbits were not protected from HTLV-I infection as determined by seroconversion to viral core proteins by immunoblot, HTLV-I p24 antigen detection in lymphocyte cultures and polymerase chain reaction for the HTLV-I provirus in lymphocyte DNA. Env-5 peptide immunization failed to induce T-cell lymphocyte proliferative responses in rabbits, but induced antibody responses in T-cell deficient Balb c nu/nu mice suggesting that the antigenic determinant represented by the Env-5 peptide is primarily a B-cell epitope. These results further define an immunodominant epitope of the HTLV-I envelope protein and suggest that potential synthetic peptide vaccines against HTLV-I infection must contain multiple antigens that induce both humoral and cellular immune reactivity.

KW - animal model

KW - human

KW - human T-lymphotropic virus type 1

KW - synthetic peptide

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=0026737339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026737339&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(92)90274-Y

DO - 10.1016/0304-3835(92)90274-Y

M3 - Article

C2 - 1360328

AN - SCOPUS:0026737339

VL - 66

SP - 11

EP - 20

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -